Oncolytics Biotech Seeks FDA Pathway for Pelareorep in Anal Cancer
Event summary
- Oncolytics Biotech scheduled a Type C FDA meeting for April 16, 2026, to discuss a single-arm registrational pathway for pelareorep in anal cancer.
- The potential study would enroll 60-70 patients with objective response rate (ORR) as the primary endpoint.
- Pelareorep in combination with a checkpoint inhibitor achieved a 30% ORR in late-line patients, compared to 10-14% in real-world outcomes.
- Anal cancer market is expected to double to $2.3 billion from 2025 to 2035.
The big picture
Oncolytics Biotech is navigating a critical regulatory pathway for pelareorep in anal cancer, a rare indication with limited treatment options. The company's strategy hinges on leveraging encouraging clinical data to secure a more efficient approval process. The anal cancer market's projected growth underscores the strategic importance of this development, particularly in the second-line and later treatment settings where outcomes remain poor.
What we're watching
- Regulatory Alignment
- How the FDA meeting will shape the statistical analysis plan and sample size for the potential pivotal single-arm study.
- Clinical Efficacy
- Whether the durability of pelareorep's response rates can sustain regulatory approval in a setting with limited approved therapies.
- Market Dynamics
- The pace at which the anal cancer market grows and how Oncolytics positions itself within this expanding landscape.
Related topics